Trump hints at leveraging trade to mandate countries and pharmaceutical firms to adopt his most preferred nation pricing policy
In a White House event in May 2025, President Trump announced an executive order aimed at reducing drug prices for Americans. The order instructed federal agencies, including the Health and Human Services Department and the Centers for Medicare and Medicaid Services, to begin implementing the Most Favored Nation (MFN) pricing policy [1]. This policy would peg U.S. drug prices to the lowest prices paid by other developed countries [2].
However, no final agreements have been made under the program, and the MFN policy is currently voluntary. As the policy is being debated among experts and policymakers, there is a lack of detailed, region-specific public perception data available from Tennessee, Texas, and Michigan as of July 2025 [1].
General expert and policy commentary suggest mixed views on the policy's impact. Some analysts warn that the reforms, including MFN pricing and actions targeting pharmacy benefit managers and the 340B program, may disincentivize drug manufacturers from offering discounts and could ultimately raise out-of-pocket costs for patients [2]. Conversely, the policy intends to align U.S. drug prices more closely with lower prices seen internationally and has prompted the Department of Health and Human Services (HHS) to identify pricing targets quickly after the order [3][4].
HHS Secretary Robert F Kennedy Jr stated that Americans pay more so others can pay less, which he said stops now [5]. President Trump reiterated that the same factory and company make the drugs in both the U.S. and other countries where they are cheaper [6]. Trump even mentioned a friend who pays $1,300 for Ozempic in the U.S., but $88 in Europe [7].
Trump's executive order has been met with silence from the Democratic party regarding their support or opposition [8]. Meanwhile, the policy has sparked concerns among some European countries, with Trump threatening to restrict car sales from Europe if they do not comply with his drug pricing policy [9]. However, Trump did not specify any new countries that may be involved in the MFN policy.
Tennessee and Michigan, with their historically high prescription drug costs affecting vulnerable populations, may hold cautious optimism about any effort to reduce prices [10]. Texas, with its large population and significant healthcare industry presence, might reflect a broader spectrum of opinions influenced by local healthcare providers, insurers, and patient advocacy groups.
As the MFN policy moves forward, it remains to be seen how it will impact drug prices for Americans and whether it will be met with widespread support or resistance. The policy's success will depend on the participation of drug manufacturers and the ability to balance price reductions with maintaining access to affordable medication for patients.
- The MFN pricing policy, as part of the executive order announced by President Trump in May 2025, aims to reduce drug prices for Americans by pegging U.S. prices to the lowest prices paid by other developed countries, but the policy is currently voluntary.
- HHS Secretary Robert F Kennedy Jr and President Trump have stated that Americans pay more for drugs so others can pay less, but some analysts have warned that the reforms may disincentivize drug manufacturers from offering discounts and could ultimately raise out-of-pocket costs for patients.
- As the MFN policy moves forward, it is important to consider the public perception data from states like Tennessee, Texas, and Michigan to gauge support or resistance, as these states have historically high prescription drug costs affecting vulnerable populations.
